Skip to main content

Table 4 Comparison of clinical and laboratory data between patients with HFS and those without HFS

From: High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study

Factor HFS
(n = 58)
Non-HFS
(n = 109)
P value
Sex Male 21(36.2%) 51(46.8%) 0.189
Female 37(63.8%) 58(53.2%)  
Age   59 ± 9.76 61 ± 14.60 0.352
BMI(kg/m2)   23.93 ± 2.17 23.34 ± 2.32 0.114
Dose intensity (mg·m2) 30 12(20.7%) 50(45.9%) 0.001*
40 46(79.3%) 59(54.1%)  
Group B symptoms Yes 25(43.1%) 39(35.8%) 0.354
No 33(56.9%) 70(64.2%)  
Clinical stage I-II 32(55.2%) 45(41.3%) 0.086
III-IV 26(44.8%) 64(58.7%)  
Presence of large tumour masses Yes 7(12.1%) 21(19.3%) 0.236
No 51(87.9%) 88(80.7%)  
Pathological type HL 11(19.0%) 13(11.9%) 0.248
NHL 47(81.0%) 96(88.1%)  
History of gallstones Yes 8(13.8%) 3(2.8%) 0.006*
No 50(86.2%) 106(97.2%)  
Hepatitis Yes 12(20.7%) 11(10.1%) 0.058
No 46(79.3%) 98(89.9%)  
Treatment cycle   5.47 ± 2.00 5.36 ± 1.52 0.721
Curative effect CR + PR 47(81.0%) 97(89.0%) 0.155
SD + PD 11(19.0%) 12(11.0%)  
Baseline ALT   30.28 ± 15.93 14.14 ± 4.91 < 0.001*
Baseline AST   29.17 ± 8.79 19.27 ± 4.29 < 0.001*
Baseline GGT   46.24 ± 35.60 19.23 ± 7.38 < 0.001*
Baseline TBIL   13.62 ± 5.04 13.51 ± 4.37 0.889
Baseline MONO   0.41 ± 0.12 0.42 ± 0.46 0.860
  1. *Abbreviations:ALT alanine aminotransferase, AST aspartate aminotransferase, GGT glutamine transpeptidase, TBIL total bilirubin, MONO monocyte count